Poly Medicure (Polymed) announced its financial results for Q3 FY26, reporting a consolidated revenue growth of 16.4%. The company’s domestic revenue increased by 16.2%. Operating EBITDA grew by 2.8%, with a margin of 24.2%. The company maintains a strong liquidity position with cash and equivalents of ₹839.8 Crs as of December 31, 2025.
Financial Highlights for Q3 FY26
Poly Medicure Limited (Polymed) has released its financial performance summary for the third quarter of fiscal year 2026, showcasing significant growth and strategic advancements.
Key financial highlights include:
- Consolidated revenue growth of 16.4% compared to Q3 FY25.
- Domestic revenue growth of 16.2% in Q3 FY26.
- Operating EBITDA grew by 2.8%, achieving a margin of 24.2%. Standalone EBITDA margin reached 26.8%.
- 9M FY26 Consolidated Operating EBITDA and PAT grew by 2.7% and 3.6% respectively; 9M Operating EBITDA margin was 25.8%.
- The company reported adequate liquidity with ₹839.8 Crs in cash and cash equivalents as of December 31, 2025. Capex spend was ₹234 Crs in 9M FY26.
Segment Performance
A detailed breakdown of sales by segment reveals the following:
- Infusion Therapy: ₹274.3 Cr in Q3 FY26, a 5.0% increase YoY.
- Renal: ₹44.8 Cr, a 15.1% increase YoY.
- Others: ₹174.6 Cr, a substantial 40.6% increase YoY.
Strategic Developments
Polymed achieved notable milestones in Q3 FY26, reinforcing its market position and innovation pipeline:
- Clinical study on RisoR stent is in progress with over 200 patients enrolled across centers in India.
- Regulatory approval was received from DCGI for the Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB).
- Deepening SARATHII Program: AI-led interactive training module is being implemented across business units gradually.
Other Updates
- Launched 19 new products in 9M FY26.
- The R&D team now consists of approximately 100+ members across India, Italy, and the Netherlands.
- Polymed was awarded the “Top 50 IP-Driven Organizations” by the Confederation of Indian Industry.
- The company was also recognized as the “Emerging Medical Devices Company of the Year in Cardiology” at VOH BEAT 2025.
Source: BSE
